Results 21 to 30 of about 589 (105)

Eltrombopag for the treatment of refractory thrombocytopenia associated with connective tissue disease

Scientific Reports, 2021
To assess the efficacy and safety of eltrombopag in connective tissue disease (CTD)-immune thrombocytopenia (ITP), we conducted this single-center retrospective observational study, including patients with refractory CTD-ITP who were treated with ...
Juan Wang, Min Dai, Qiong Fu, Sheng Chen
doaj   +1 more source

Use of Thrombopoietin Receptor Agonists in Pregnancy: A Review of the Literature

Hematology/Oncology and Stem Cell Therapy, 2022
The management of immune thrombocytopenic purpura (ITP) involves several lines of therapy such as corticosteroids and intravenous immunoglobulin. With the emergence of novel therapies such as thrombopoietin receptor agonists (TPO-RAs), there has been a ...
Jude Howaidi, Abdullah M. AlRajhi, Ali Howaidi, Fouad H. AlNajjar, Imran K. Tailor   +4 more
doaj   +1 more source

Intermittent versus Daily Eltrombopag Dosage Protocols for the Treatment of Primary Immune Thrombocytopenia: Real-Life Experience

Journal of Blood Medicine, 2020
Tamer A Elbedewy,1 Mohamed A Elsebaey,1 Reem A Elkholy,2 Dina M Tahoon,2 Samah A Elshweikh1 1Internal Medicine Department, Faculty of Medicine, Tanta University, Tanta, Egypt; 2Medical Pharmacology Department, Faculty of Medicine, Tanta University, Tanta,
Elbedewy TA, Elsebaey MA, Elkholy RA, Tahoon DM, Elshweikh SA   +4 more
doaj  

Evaluation of safety, efficacy and pharmacokinetics of Eltrombopag in patients with chronic immune thrombocytopenia: Meta-analysis of randomized controlled trials Authors

Research Results in Pharmacology, 2023
Introduction: Immune thrombocytopenia (ITP) is a complex autoimmune syndrome associated with low platelet count. Eltrombopag is an oral thrombopoietin receptor agonist that used in the treatment of chronic ITP.
Abdullah AL-Dhuraibi, Ahmad Khalaf Alkhawaldeh, Wadah Mohammed Al-Dhuraibi, Anna A. Peresypkina   +3 more
doaj   +1 more source

Impact of Eltrombopag Therapy in Different Lines of Treatment on Response in Patients with Immune Thrombocytopenia

İstanbul Medical Journal
Introduction: This study aimed to evaluate the results obtained with the preference of eltrombopag according to the line of treatment in patients diagnosed with ITP.
Abdülkadir Karışmaz, Vahit Can Çavdar, Istemi Serin, Rafet Eren   +3 more
doaj   +1 more source

In vitro effect of eltrombopag alone and in combination with azacitidine on megakaryopoiesis in patients with myelodysplastic syndrome

Platelets, 2021
Thrombocytopenia is a severe complication for patients with myelodysplastic syndrome (MDS). Eltrombopag increases platelet count in MDS patients but its combination with azacitidine elicited controversial results.
Francesco D’Alò, Ilaria Zangrilli, Elisa Cupelli, Luana Fianchi, Marianna Criscuolo, Giulia Falconi, Emiliano Fabiani, Livio Pagano, Stefan Hohaus, Valerio De Stefano   +9 more
doaj   +1 more source

Predicting response of severe aplastic anemia to immunosuppression combined with eltrombopag

Haematologica, 2021
Pretreatment blood counts, particularly an absolute reticulocyte count ≥25×109/L, correlate with response to immunosuppressive therapy in severe aplastic anemia.
Yoshitaka Zaimoku, Bhavisha A. Patel, Ruba Shalhoub, Emma M. Groarke, Xingmin Feng, Colin O. Wu, Neal S. Young   +6 more
doaj   +1 more source

Transcriptomic analysis of patients with immune thrombocytopenia treated with eltrombopag

Platelets, 2020
In the last years, the use of thrombopoietin receptor agonists (TPO-RA), eltrombopag and romiplostim, has improved the management of immune thrombocytopenia (ITP).
Jesús María Hernández-Sánchez, José María Bastida, Diego Alonso-López, Rocío Benito, José Ramón González-Porras, Javier De Las Rivas, Jesús María Hernández Rivas, Ana Eugenia Rodríguez-Vicente   +7 more
doaj   +1 more source

Eltrombopag Added to Standard Immunosuppressive Treatment as Front‐Line Therapy for Severe Aplastic Anemia: Long‐Term Outcomes of the Phase‐3 Randomized Superiority EBMT‐SAAWP RACE Study

American Journal of Hematology, EarlyView.
ABSTRACT The RACE study (NCT02009747) compared horse antithymocyte globulin (hATG) plus cyclosporine A (CsA) ± eltrombopag as initial immunosuppressive treatment (IST) for severe aplastic anemia. Here we report the final 2‐year analysis of this prospective randomized phase III study.
Antonio M. Risitano, Simona Iacobelli, Austin Kulasekararaj, Marleen van Os, Sofie R. Terwel, Joe Tuffnell, Brian Piepenbroek, Morag Griffin, Constantijn J. M. Halkes, Christian Recher, Fiorenza Barraco, Edouard Forcade, Juan Carlos Vallejo, Beatrice Drexler, Jean‐Baptiste Mear, Roochi Trikha, Shreyans Gandhi, Anna Maria Raiola, L. G. M. Daenen, Marco R. de Groot, Etienne Daguindau, Erfan Nur, Wilma Barcellini, Nigel H. Russell, Louis Terriou, Anna Paola Iori, Walter Barberi, Anna Sureda, Isabel Sánchez‐Ortega, Blanca Xicoy, Isidro Jarque, James Cavenagh, Flore Sicre de Fontbrune, Camilla Frieri, Talha Munir, Jennifer M. L. Tjon, Suzanne Tavitian, Aline Praire, Laurence Clement, Florence Rabian, Luana Marano, Anita Hill, Elena Palmisani, Petra Muus, Serena Marotta, Fabiana Cacace, Marica Laurino, Jakob R. Passweg, Gérard Socié, Ghulam J. Mufti, Carlo Dufour, Régis Peffault de Latour, Severe Aplastic Anaemia Working Party of the EBMT   +52 more
wiley   +1 more source

Avatrombopag for persistent and chronic immune thrombocytopenia in children: A post hoc analysis of clinical characteristics of response from a phase 3b clinical trial

British Journal of Haematology, EarlyView.
Summary Avatrombopag treatment resulted in significantly higher platelet response rates in patients when compared with placebo in a phase 3b study of patients with paediatric immune thrombocytopenia (ITP) (NCT04516967). These post hoc analyses of the 12‐week core phase further assessed the efficacy of avatrombopag, considering the influence of baseline
Rachael F. Grace, Göksel Leblebisatan, Yesim Aydinok, Sule Unal, John Grainger, Amanda B. Grimes, Michele P. Lambert, Jessica Zhang, Brian D. Jamieson, Faizan Sattar, Scott Kolodny, Michael Vredenburg, on behalf of the AVA‐PED‐301 Study Group   +12 more
wiley   +1 more source